compounding pharmacy tirzepatide lawsuit FDA confirms shortage is still over, gives compounders a grace period Compound Tirzepatide

much lower at community doses Vomiting up to 36% at high doses Diarrhea 23-26% Constipation 17-19% Fatigue 11-13% Pancreatitis risk trials flagged severe abdominal pain for discontinuation and evaluation Gallbladder issues rapid weight loss increases gallstone risk Thyroid C-cell tumors same boxed warning as semaglutide (animal studies) GI side effects were more intense than semaglutide in trial data due to the dual mechanism

This will be decided between you and your prescriber

Efficacy Semaglutide : Effective in reducing blood sugar levels and body weight

The options may be chosen on the product page

Zepbound has FDA approval for two main uses: Chronic weight management in adults with obesity or adults who are overweight with one or more obesity-related health conditions